Kevin Killeen | Chief Scientific Officer
2K Biologics LLC

Kevin P Killeen, PhD is the President of 2K Biologics LLC, a biologics consulting company.  Dr. Killeen has extensive training in the fields of molecular biology, microbiology, protein chemistry, immunology, and vaccinology.  His undergraduate BS degree is from Stonehill College (biology and chemistry), Ph. D from University of Rhode Island (microbiology), and post-doctoral fellowship at Harvard Medical School (molecular genetics and protein toxin chemistry).  Dr Killeen has 35 years of experience in the field of biotechnology at IDEXX Corp., VRI/AVANT-Celldex Inc, and Chief Scientific Officer at Matrivax Corp.  He has published > 30 vaccine manuscripts, authored four chapters, written several science reviews, is an inventor on 15 patent/applications, and served for 13 years as a member of the URI Dean’s Advisory Council.  Dr. Killeen was the principal investigator (PI) on vaccine related grants and contracts exceeding $11 MM and coordinated greater than $13 MM in funding from the Bill & Melinda Gates Foundation.  Career highlights include the commercialization of two diagnostic tests, directing nine (9) vaccine candidates (live-attenuated/oral and subunit/injectable) into Phase 1 and 2 clinical trials, and guiding the clinical development of CholeraGarde®, an oral, single-dose cholera vaccine towards a Phase 3 clinical trial and out-licensing.  Moreover, while at VRI, Dr. Killeen identified and performed scientific due diligence on rotavirus vaccine candidate 89-12, advanced through Phase 2b studies and ultimately out-licensed to GSK and commercialized as Rotarix®, a >$1 billion ‘blockbuster’ vaccine. While at Matrivax, Dr. Killeen identified, in-licensed, and developed a pneumococcal vaccine candidate, MVX01, that has completed non-human primate (NHP) challenge and Phase 1a clinical studies.